Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00037713
Status:
COMPLETED
Last Update Posted:
2010-04-08
First Post:
2002-05-20
Brief Title:
Survival in a Randomized Phase III Trial in Patients With Limited Disease LD Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Organization Data
Organization:
Eli Lilly and Company
Class:
INDUSTRY
Study ID:
SILVA EORTC 08971
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Eli Lilly and Company
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Chief Medical Officer
Old Organization:
ImClone LLC
Collaborators
| Name | Class |
|---|---|
| Independent centers Australia New Zealand Europe USA | UNKNOWN |
| Merck KGaA Darmstadt Germany | INDUSTRY |
| EORTC Lung Cancer Cooperative Group | OTHER |
| Spanish Lung Cancer Group | OTHER |
| Schweizerische Arbeitsgruppe fuer angewandte Krebsforschung SAKK | UNKNOWN |
| US Department of Veterans Affairs | FED |
| Groupe Francais De Pneumo-Cancerologie | OTHER |
| Memorial Sloan Kettering Cancer Center | OTHER |